Subliminal Diode Treatment of the Ciliary Bodies by Transscleral Cyclophotocoagulation with a 31.3% Duty Cycle in the Treatment of Refractory Glaucoma: Safety and Efficacy

Zerin Hekalo, Karine Angioï, Etselle Neiter, Jean-Baptiste Conart and Toufic Maalouf*

Department of Ophthalmology, CHRU-Nancy, France

*Corresponding author: Toufic Maalouf, Department of Ophthalmology, Nancy-Brabois University Hospital, Rue du Morvan, 54500 Vandoeuvre les Nancy, France, Tel: +33-33-83-15-30-29, Fax: +33-33-83-15-51-09

Abstract

Purpose: Micropulse Transscleral diode laser cyclophotocoagulation (MP-TSCPC) is an established method of treatment for refractory glaucoma. This study evaluates the efficacy in terms of reduction in intraocular pressure and/or treatment amount, and safety and side effects of the ciliary bodies using a subthreshold laser with a duty cycle of 31.3% with Supra 810 nm Subliminal Quantel Medical, at one year in patients with refractory glaucoma.

Methods: A retrospective, observational, single-center study conducted between January 2019 and November 2019 at Nancy University Hospital, includes 22 eyes. The inclusion criteria was patients with refractory glaucoma, defined as glaucoma with no longer response to medical or surgical treatment and/or painful eye. The exclusion criteria was eye which received any other procedure in order to destroy or weaken the ciliary body. All patients were reviewed at one week, one month and one year in post-operative period. Aetiology of glaucoma, history of surgery, change in intraocular pressure (IOP), glaucoma medication, visual acuity, pain symptoms, assessment of ocular surface pathology, and complication rate were documented.

Results: The study included 22 patients: 9 patients were female and 13 patients were male, and the mean age was 71.4 ± 15 years. The pre-operative mean IOP was 37.5 ± 8 mmHg and 26.5 ± 12 mmHg after laser procedure. The mean IOP reduction was 44.8% at one week, 30.4% at one month and 29.3% at one year after treatment, which was statistically significant (P value < 0.05, paired Student’s t-test). 93.7% of patients had improvement in pain symptoms after MP-TSCPC. The assessment of the surface pathology showed improvement in Oxford score that fell from 1.3 to 1. The mean number of ocular antihypertensive medication used was 2.2 before treatment and decreased to 1.7 one year after treatment, which represent a reduction of 25.1% of treatment score. All patients had unchanged visual acuity post-operatively except two. No significant complications or anatomic modifications were found after subliminal cyclophotocoagulation.

Conclusion: Subliminal cyclophotocoagulation with 31.3 duty cycle is effective and safe procedure for reducing IOP and/or pain in cases of refractory glaucoma.

Keywords

Glaucoma/therapy, Intraocular pressure, Micropulse transscleral cyclophotocoagulation

Introduction

Glaucoma is a progressive optic neuropathy that can lead to vision loss if left untreated [1]. Treatment involves lowering intraocular pressure to delay disease progression [2], either through local medical treatment (eye drops), surgical treatment (filtering surgery) or physical means (lasers). A new subthreshold diode laser therapy involving the treatment of the ciliary bodies has been developed: An infrared laser (810 nm) that targets the ciliary processes to reduce aqueous humour secretion [3]. The objective of our study was to evaluate its efficacy in terms of reduction in intraocular pressure and/or number of eye drops applied, as well as to assess the safety and side effects of the subliminal diode treatment of the ciliary bodies with a subthreshold laser at one year in patients with refractory glaucoma.
Patients, Materials and Methods

This was a retrospective, observational, single-centre study conducted between January 2019 and November 2019 at Nancy University Hospital.

The inclusion criterion was the existence of refractory glaucoma. Refractory glaucoma is glaucoma that is painful and/or no longer responding to medical or surgical treatment. We excluded any patients who had previously received another procedure designed to destroy or weaken the ciliary processes.

The surgical procedure was performed by a single operator. The laser used in our department is the Vitra 810 SubCyclo laser (Quantel Medical, Cournon d’Auvergne, France).

The procedures were performed under sterile conditions in the operating room and the subjects were treated as outpatients. The laser was applied to 3 mm of the limbus without prior identification of the position of the ciliary processes by transscleral illumination. The laser power was set to 2 W. The exposure time was 80 seconds per semi-circumference with a duty cycle of 31.3%. The probe was held perpendicular to the limbus, maintaining contact with the sclera while sliding it parallel to the limbus over the upper semi-circumference and then the lower, respecting the 3 and 9 o’clock meridians. The patient was asked not to modify their local pressure-lowering treatment during the immediate post-operative period. Topical steroid anti-inflammatory treatment was initiated post-operatively for 1 month. All patients were reviewed at one week, one month and one year.

We recorded each patient’s age, sex, initial diagnosis, affected side, history of filtering surgery and treatments at the time of the procedure. At each visit we measured visual acuity, performed a slit lamp examination to look for signs of local inflammation and score the ocular surface condition based on the Oxford grading scale (Figure 1), and measured IOP using the Goldmann applanation tonometer. We also rated pain on a numeric scale (NS) from zero (no pain) to 10 (maximum pain), asking the patient to estimate pain before and after treatment. Pressure-lowering treatment (local and general) was also scored. In order to quantify the initial and final medical treatment, we assigned one point for a single eye drop and two points for a combination of eye drops. Similarly, one point was assigned if general treatment with oral acetazolamide was required.

| PANEL | GRADE | CRITERIA |
|-------|-------|----------|
| A     | 0     | Equal to or less than panel A |
| B     | I     | Equal to or less than panel B, greater than A |
| C     | II    | Equal to or less than panel C, greater than B |
| D     | III   | Equal to or less than panel D, greater than C |
| E     | IV    | Equal to or less than panel E, greater than D |
| >E    | V     | Greater than panel E |

Figure 1: Oxford grading scale for assessing the ocular surface condition.
tant to maximum eye drop treatment (36.4%), 7 cases of neovascular glaucoma (NVG, 31.8%), 3 cases of inflammatory glaucoma (IG, granulomatous panuveitis, 4.5%), 2 cases of congenital glaucoma (CG, 9.1%), 1 case of intraocular hypertension glaucoma secondary to silicone oil retinal tamponade (IOHT SOT, 4.5%) and 1 case of malignant glaucoma (MG, 4.5%) (Table 2).

### Surgical history
Fifteen eyes (68.2%) had undergone filtering surgery (14 trabeculectomies and 1 non-penetrating sclerectomy). Seven patients had received no prior filtering surgery. Fifteen patients (68.2%) were pseudophakic and seven patients (31.8%) were phakic with early to severe cataracts.

### Intraocular pressure
The pre-operative mean IOP was 37.5 ± 8 mmHg, with a range of 22 mmHg to 58 mmHg (Figure 2). The following mean IOPs were

---

### Table 1: General characteristics of the patients studied.

| Age (years) | Sex | Side | Type of anaesthesia | Lens status | History of filtering surgery | Pre-operative IOP (mmHg) | Pre-operative pain (NS) |
|------------|-----|------|---------------------|-------------|------------------------------|--------------------------|-------------------------|
| M 13 (59.1%) | Right 10 (45.4%) | GA 11 (50%) | Pseudophakic 15 (68.2%) | Filtering surgery 15 (68.2%) | 35.1 | |
| F 9 (40.9%) | Left 12 (54.6%) | PBA 11 (50%) | Phakic 7 (31.8%) | Naive 7 (31.8%) | 36.6 | |

71.9 ± 15

IOP: Intraocular pressure; NS: Numeric pain scale (0–10); GA: General anaesthesia; PBA: Peribulbar anaesthesia.

The study criteria were analysed:
- Pre-operative and post-operative IOP at 12 months regardless of cause and then according to aetiology (paired Student’s t-test with significant results for p < 0.05).
- The difference between the number of pressure-lowering treatments before and after the operation (paired Student’s t-test with significant results for p < 0.05).

The laser treatment was considered to be effective if the pain resolved and/or IOP was less than or equal to 21 mmHg.

### Results

#### Pre-operative results

Nine women (40.9%) and 13 men (59.1%) were included between January 2019 and November 2019: A total of 22 subthreshold cyclodiode laser procedures for refractory glaucoma. The average age was 71.4 ± 15 years, with a range of 40 to 89 years. Two patients required a second treatment procedure. There were a total of 10 right eyes (45.4%) and 12 left eyes (54.6%). The procedure was performed under general anaesthesia for 11 eyes (50%) and under local or regional (peribulbar) anaesthesia for the other 11 (50%). The characteristics of our population are summarised in Table 1.

### Initial diagnosis
The initial diagnosis comprised: 8 cases of primary open-angle glaucoma (POAG) resistant to maximum eye drop treatment (36.4%), 7 cases of neovascular glaucoma (NVG, 31.8%), 3 cases of inflammatory glaucoma (IG, granulomatous panuveitis, 4.5%), 2 cases of congenital glaucoma (CG, 9.1%), 1 case of intraocular hypertension glaucoma secondary to silicone oil retinal tamponade (IOHT SOT, 4.5%) and 1 case of malignant glaucoma (MG, 4.5%) (Table 2).

### Table 2: Distribution of refractory glaucoma aetiologies in the study population.

|     | POAG | NVG | IG | CG | IOHT SOT | MG |
|-----|------|-----|----|----|----------|----|
|     | 8    | 7   | 3  | 2  | 1        | 1  |

POAG: Primary open-angle glaucoma; NVG: Neovascular glaucoma; IG: Inflammatory glaucoma; CG: Congenital glaucoma; IOHT SOT: Intraocular hypertension with silicone oil retinal tamponade; MG: Malignant glaucoma.

---

Figure 2: Change in intraocular pressure at 12 months for our 22 treated eyes.
found: 35.7 mmHg in the primary open-angle glaucoma group, 36.7 mmHg for neovascular glaucoma, 28 mmHg for inflammatory glaucoma, 37 mmHg for congenital glaucoma, 26 mmHg for hypertension caused by retinal detachment with silicone oil retinal tamponade, and 50 mmHg for malignant glaucoma (Table 3).

**Pain:** Pain was present in 16 patients, with an average of 3.1 on a numeric pain scale (range 0-10) (Table 4).

**Biomicroscopic examination:** Inflammation of the ocular surface related to glaucoma medications was assessed by the Oxford score (Figure 1). The average score for the population was 1.3.

**Initial treatment:** Pre-operatively, the distribution of the number of eye drops was as follows: 1 eye (4.5%) with monotherapy, 2 eyes (9.1%) with dual therapy, 8 eyes (36.4%) with triple therapy and 11 eyes (50%) with quadruple therapy. Seven patients (27.8%) were also receiving general treatment with oral acetazolamide (Diamox) (Table 5).

**Visual acuity before treatment:** Visual acuity ranged from light perception to 7/10 (Parinaud scale). For 17 patients (77.27%) it was less than 1/10; only 5 patients (22.72%) had superior vision. Table 6 summarises the visual acuity values.

**Post-operative results**

**Post-operative intraocular pressure (Figure 2):** We noted a decrease in mean intraocular pressure of 44.8% on D7, 30.40% at M1 and 29.30% at 1 year, with a statistically significant difference at 1 week (p = 0.001) and 1 year (p = 0.008). The data are shown in the Table 7.

**Table 3:** Distribution of mean IOP values by aetiology.

| Aetiology       | Number (n) | Pre-operative IOP (mmHg) |
|-----------------|------------|--------------------------|
| POAG            | 8          | 35.7                     |
| NVG             | 7          | 36.7                     |
| IG              | 3          | 28                       |
| CG              | 2          | 37                       |
| IOHT SOT        | 1          | 26                       |
| MG              | 1          | 50                       |

POAG: Primary open-angle glaucoma; NVG: Neovascular glaucoma; IG: Inflammatory glaucoma; CG: Congenital glaucoma; IOHT SOT: Intraocular hypertension with silicone oil retinal tamponade; MG: Malignant glaucoma

**Table 4:** Mean pre-operative pain.

| Pre-op         |          |
|----------------|----------|
| Pain           | 16 (72.7%) |
| No pain        | 6 (27.3%)  |
| Mean numeric scale score | 3.1       |

**Table 5:** Summary of baseline treatments and therapeutic scores.

| Treatments       | Number | Pre-operative cumulative score |
|------------------|--------|--------------------------------|
| Monotherapy      | 1 (4.5%) | 1                             |
| Dual therapy     | 2 (9.1%) | 4                             |
| Triple therapy   | 8 (36.4%) | 16                            |
| Quadruple therapy| 11 (50%) | 22                            |
| Diamox           | 7 (27.8%) | 7                             |
| Total therapeutic score | 2.2       |

**Table 6:** Pre- and post-operative visual acuity, by number of patients.

| Initial VA | n | VA at 1 year | n |
|------------|---|--------------|---|
| LP-        | 3 (13.6%) | LP- | 3 (13.6%) |
| LP+        | 9 (40.9%) | LP+ | 9 (40.9%) |
| HM         | 3 (13.6%) | HM | 3 (13.6%) |
| CF1        | 2 (9.1%) | CF1 | 2 (9.1%) |
| 1/-10      | 1 (4.5%) | 1/-10 | 1 (4.5%) |
| 1.5/10     | 1 (4.5%) | 1/20  | 1 (4.5%) |
| 2/-10      | 1 (4.5%) | 2/-10 | 1 (4.5%) |
| 4/-10      | 1 (4.5%) | 2.5/10 | 1 (4.5%) |
| 7/-10      | 1 (4.5%) | 7/-10 | 1 (4.5%) |

LP: Light perception; HM: Hand motion; CF1: Counting fingers at 1 meter

**Table 7:** Summary table of intraocular pressure data.

| D0 | D7 | M1 | 1Y | P  |
|----|----|----|----|----|
| Number | 22 | 22 | 22 | 22 |
| Mean IOP | 35.7 | 21.2 | 27.2 | 26.4 | 0.05 |
| Standard deviation | 8.9 | 8 | 12.3 | 12.2 |
| Max. IOP | 58 | 42 | 50 | 60 |
| Min. IOP | 22 | 8 | 7 | 10 |
| Reduction in IOP (%) | 44.80% | 30.40% | 29.30% | 0.006 |
| IOP < 21 | 0 | 11 (50%) | 5/15 (33.3%) | 7 (31.8%) |
| SD | 8.9 | 8 | 12.3 | 12.2 |
| t-value | 6.15 | 2.34 | 2.93 |
| p-value | 0.001 | 0.035 | 0.008 |
Post-operative pain: We saw an improvement in pain in 15 out of the 16 eyes that were reported to be painful at the outset. Nine eyes were no longer painful at all and 6 others were less painful. Of the 7 that remained painful, 4 had neovascular glaucoma with significant ocular hypertension initially, one of which presented an increase in post-operative hypertension at 1 year. The last patient with constant pain had malignant glaucoma with increased ocular hypertension: The treatment failed (Table 8).

Biomicroscopic examination: Assessment of surface pathology by Oxford score showed stability for most patients, with a mean score that fell from 1.3 to 1. Three eyes saw an improvement in the condition of the ocular surface. These were two neovascular glaucoma cases and one eye with silicone oil retinal tamponade following retinal detachment.

Change in local treatment during the post-operative period: The mean number of pressure-lowering medical treatments was 2.2 pre-operatively compared to 1.7 post-operatively at one year. For patients who were on local and general treatment, the normalisation of their IOP enabled them to stop or reduce oral acetazolamide. One patient with primary open-angle glaucoma with no history of filtering surgery was no longer taking any local or general medical treatment. There was a significant difference (p = 0.006) in the reduction in medical treatment at 1 year (p < 0.05, paired Student’s t-test) (Table 9).

Post-operative visual acuity: All patients had unchanged visual acuity post-operatively except two. One pseudophakic eye with congenital glaucoma saw its visual acuity halve, from 4/10 to 2.5/10. The other pseudophakic eye with primary open-angle glaucoma saw its acuity drop from 1.5/10 to 1/20. No retinal aetiology was found to explain this decrease in visual acuity in these two patients. Of the other eyes with visual acuity greater than or equal to 1/10, they maintained useful visual acuity (Table 6).

Summary: The various data on pain, intraocular pressure and post-operative therapeutic score at one year are shown in Table 10.

Detailed Results for Each Group

Primary open-angle glaucoma (POAG) (n = 8)

The initial mean IOP was 34.8 ± 7.6 mmHg, dropping to 20.1 ± 8.9 mmHg at 1 year (Figure 3). The decrease in IOP at 1 year was 42.2% (p = 0.009). The mean pain scale score fell from 3.2 to 0 at 1 year post-operatively.

Clinical examination including inflammation and Oxford grading remained unchanged at 1 year, with an average Oxford score of 0.75.

The therapeutic score fell from 2.25 to 2.1 at 1 year post-operatively.

Table 8: One-year post-operative results for pain.

|                  | Pre-operative | 1 year post-operative |
|------------------|---------------|-----------------------|
| In pain          | 16 (72.7%)    | 7 (31.8%)             |
| No pain          | 6 (27.3%)     | 15 (68.2%)            |
| NS               | 3.1           | 0.7                   |

Table 9: Change in therapeutic score at one year post-operatively.

|                  | Pre-operative | 1 year post-operative | p-value |
|------------------|---------------|-----------------------|---------|
| Therapeutic score| 2.2           | 1.7                   | 0.017   |

Table 10: Summary data.

| IOP (mmHg) | Pain | Therapeutic score |
|------------|------|-------------------|
| Before     | After| Before            | After   | Before | After   |
| 37.5 ± 8.6 | 26.5 ± 12.5| 16 (72.7%) | 7 (31.8%)| 2.2    | 1.7     |

Figure 3: Change in IOP in the primary open-angle glaucoma group (POAG).
Clinical examination revealed surface pathology with an unchanged Oxford score of 2 pre- and post-operatively at one year.

The therapeutic score dropped from 2.3 to 1.3 one year after laser treatment.

None of the treated eyes had any useful visual acuity.

Congenital glaucoma (CG) (n = 2)

In this group, the initial mean IOP was 37 ± 7 mmHg and fell to 25.5 ± 0.7 mmHg at 1 year, which represents an average decrease in IOP of 31.1%, but this difference was not statistically significant (p = 0.237) (Figure 6). The mean numeric pain scale score fell from 3.5 to 1.4 one year after laser treatment.

The clinical examination showed no inflammatory signs before or after treatment.

The therapeutic score remained unchanged at 2.

One eye had a pre-operative visual acuity of 4/10, which decreased to 2.5/10 post-operatively.

Ocular hypertension with inflammatory glaucoma (IG) (n = 3)

The mean IOP value in this group fell from 28 ± 7.2 mmHg to 21 ± 1.4 mmHg at 1 year, which represents a mean reduction of 25%, but this difference was not statistically significant (p = 0.157) (Figure 5). The mean numeric pain scale score fell from 1.3 to 0.3.

Two patients had a useful visual acuity of greater than or equal to 1/10 pre-operatively compared to a single patient post-operatively.

Neovascular glaucoma (NVG) (n = 7)

In this group, the initial IOP was 39.6 ±10.2 mmHg, falling to 31.1 ± 17.1 mmHg at 1 year, resulting in an average pressure drop of 36.9% (p < 0.05) (Figure 4). Pain fell from a mean numeric scale score of 5.4 to 1.4 one year post-operatively.

Clinical examination remained stable, with the Oxford score dropping from 1.8 at baseline to 1.5 one year after treatment.

The therapeutic score fell from 2.28 initially to 1.8 one year after treatment.

Only one patient had useful visual acuity (measured at 2/10) that remained the same post-operatively.

Ocular hypertension with retinal detachment and silicone oil tamponade (IOHT SOT) (n = 1)

The initial IOP was 26 mmHg and increased to
Changes in IOP by aetiology are summarised in Table 11.

**Discussion**

In our study, the use of subliminal cyclodiode with a 31.3% duty cycle demonstrated a statistically significant efficacy in terms of a reduction in both intraocular pressure and pain after one year.

Laser destruction of the ciliary bodies is a technique designed to reduce aqueous humour production and therefore intraocular pressure and pain in highly painful and advanced glaucoma. Up until ten years ago, the only available procedure was thermal cyclodestruction of the ciliary bodies using an Nd: YAG 1064 nm laser [4, 5]. This treatment generated numerous inflammatory complications and the outcome was unpredictable in the long term, sometimes even resulting in phthisis bulbi [4-6]. A new technique has appeared in recent years with the introduction of the diode laser (810 nm), followed by the SubCyclo [7] micropulsed diode laser, which has improved results by reducing complications. This laser can target the pigmented cells of the ciliary epithelium, because absorption by melanin in pigment-
Table 11: Summary of change in IOP in each group.

|      | D0  | D7  | M1  | 1Y  |
|------|-----|-----|-----|-----|
| POAG | 34.8| 18.6| 18  | 20.1|
| NVG  | 42.5| 19  | 20  | 26.8|
| IG   | 28  | 18  | ND  | 21  |
| CG   | 37  | 25  | 27.5| 25.5|
| IOHT SOT | 26  | 8   | ND  | 34  |
| MG   | 29  | 23  | 50  | 50  |

POAG: Primary open-angle glaucoma; NVG: Neovascular glaucoma; IG: Inflammatory glaucoma; CG: Congenital glaucoma; IOHT SOT: IOHT caused by retinal detachment, with internal silicone oil tamponade; MG: Malignant glaucoma.

ed cells is three times greater at 810 nm, meaning this mode of operation results in improved efficacy with less inflammation. Energy is delivered in two cycles: The ON cycle, which causes photoacoagulation, followed by the OFF cycle, which allows cooling of adjacent tissues by remaining below the photoacoagulation threshold. There is therefore a marked decrease in long-term complications with a more predictable effect in terms of IOP reduction [8,9]. It has also been shown that the microanatomy of the ciliary processes is respected following the use of this laser, thanks to the cyclic mode of energy delivery. This mode minimises the harmful effects on the surrounding tissue by avoiding the disruption of the ciliary body, epithelium and ciliary processes observed under histological examination after using the transscleral laser [10].

The subthreshold laser was first used in the field of medical retina and several studies have been published on this use [11-17]. Pollack, et al. [15] conducted a preclinical study to refine the parameters and define the subliminal threshold. Parodi, et al. [12] found that the subthreshold laser was more effective than the krypton laser in the treatment of macular oedema. Li, et al. [17] observed that the micropulsed diode laser induces a reduction in inflammatory mediators in the retinal pigment epithelium, which slows down the cell stress and tissue heating responsible for protein denaturation. Laursen, et al. [13] demonstrated stabilisation or even improvement in clinically significant diabetic macular oedema and a lower rate of complications. Moorman, et al. [14] demonstrated that the subthreshold laser is delivered specifically to the pigment epithelium in the treatment of ischaemic macular oedema and diabetic retinopathy and leads to fewer complications.

These results encouraged the use of the subthreshold laser in glaucoma. A decrease in IOP of between 30 and 40% was observed at 1 year, according to the literature [18-21]. Better tolerance than the continuous mode diode laser is noted, including significantly less inflammation and rare adjacent tissue damage (scleral thinning, conjunctival burning).

The objective of our study was to evaluate the efficacy, safety and side effects of this treatment after one year in a population with refractory and/or painful glaucoma. We saw a reduction in overall IOP at 1 year of 29.3%. IOP reduction is seen as early as the first week and this could be explained by an increase in aqueous humour outflow via the uveoscleral route. This has already been observed in in vitro studies of transscleral cycloablation, such as the study by Schubert, which observed this phenomenon in pig and human eyes [22], and the study by Liu, et al. [23], which observed histological changes that indirectly explain the increase in uveoscleral outflow. A recent literature review confirmed the drop in intraocular pressure with decreased aqueous humour production and better uveoscleral
that the power level used impacts the drop in pressure difference with a duty cycle of 31.3%. Studies have shown an exposure time of 80 seconds per semi-circumfering the treatment parameters. We used 2 W of power of these failures, consideration could be given to changing the treatment parameters. The pressure-lowering trend appeared to be present in the eye at the time of clinical observation, meaning that no definitive conclusions can be drawn. The identified critical threshold (efficacy/safety) appears to be 112 to 115 J - or 90 seconds per hemisphere with 2 W and 31.3% - for the upper threshold value, because above 200 J the reduction in IOP would increase but would also be associated with more significant complications (inflammatory complications or total destruction leading to phthisis bulbi) [24,30].

In terms of complications, the onset of macular oedema has been described with the transscleral laser, whereas multiple studies have demonstrated the safety of the micropulsed laser due to the absence of any thermal effect when treating macular disease (central serous chorioretinopathy, diabetic oedema, oedema secondary to venous occlusions). Some authors reported transient loss of vision during the first months of treatment [24]. In our study, we found deterioration of visual acuity in just two cases (1 POAG and 1 CG). While the majority of our patients had reduced vision at baseline, this vision did not deteriorate. We found no clear explanation - retinal or otherwise - for the loss of vision in our two patients. It could be useful to conduct a prospective study with OCT (optical coherence tomography) before and after subthreshold laser treatment [28], but this was not possible for us due to the retrospective nature of this study.

With regard to medical treatment, we also noted a reduction in the average number of treatments, from 2.2 to 1.7 at 1 year. Although the definition of treatment success does not take into account the post-operative use of local and general treatments, reducing pressure-lowering eye drops has a significant impact on maintaining patient quality of life. For all cases, the therapeutic score decreased by 25.1%, consistent with the results of other studies, in which reduction rates range from 20 to 53% [8,9,18,20,25,26,31].

Conclusion

Our study shows a reduction in IOP and pain at one year in refractory glaucoma patients treated with sub-threshold transscleral cyclophotocoagulation (SubCyclo) with a 31.3% duty cycle, 80s per hemisphere and 2W of power. Despite the retrospective observational nature of the study and the small population size, we believe that this technique is useful in the management of refractory glaucoma.

Given that this technique results in far fewer complications than conventional transscleral diode laser, consideration could be given to extending the indication to include patients with refractory glaucoma and a relatively good level of visual acuity. Comparative and prospective studies with standardised success criteria and long follow-up periods, would enable the ideal parameters to be determined prior to any such extension of indication.
The ciliary body location varying between patients and even among quadrants of a same eye, it would be interesting to evaluate the impact of the probe positioning and speed of movement on clinical outcomes.

Ciliary body transillumination on patients prior to cyclodiode laser treatment should probably be considered in order to ensure optimal probe placement and motion velocity during the treatment.

References

1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, et al. (2014) Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology 121: 2081-2090.

2. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, et al. (2002) Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Tri.

3. Pastor SA, Singh K, Lee DA, Juzych MS, Lin SC, et al. (2002) Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 120: 1268-1279.

4. Hampton C, Shields MB, Miller KN, Blasini M (1990) Evaluation of a protocol for transscleral neodymium: YAG cyclodocoagulation in one hundred patients. Ophthalmology 97: 910-917.

5. Klapk MM, Wandel T, Donnenfeld E, Perry HD (1988) Transscleral neodymium:YAG thermal cyclodocoagulation in refractory glaucoma. A preliminary report. Ophthalmology 95: 719-722.

6. Simmons RB, Shields MB, Blasini M, Wilkerson M, Stern RA (1991) Transscleral Nd:YAG laser cyclodocoagulation with a contact lens. Am J Ophthalmol 112: 671-677.

7. Gupta N, Weinreb RN (1997) Diode laser transscleral cyclodocoagulation. J Glaucoma 6: 426-429.

8. Aquino MCD, Barton K, Tan AMWT, Sng C, Li X, et al. (2015) Micropulse versus continuous wave transscleral diode cyclodocoagulation in refractory glaucoma: a randomized exploratory study. Clin Exp Ophthalmol 43: 40-46.

9. Emanuel ME, Grover DS, Fellman RL, Godfrey DG, Smith O, et al. (2017) Micropulse Cyclodocoagulation: Initial Results in Refractory Glaucoma. J Glaucoma 26: 726-729.

10. Pantcheva MB, Kahook MY, Schuman JS, Rubin MW, Noecker RJ (2007) Comparison of acute structural and histopathological changes of the porcine ciliary processes after endoscopic cyclodocoagulation and transscleral cyclodocoagulation. Clin Exp Ophthalmol 35: 270-274.

11. Sivaprasad S, Sandhu R, Tandon A, Sayed-Ahmed K, McHugh DA (2007) Subthreshold micropulse diode laser cyclodocoagulation for clinically significant diabetic macular edema: A three-year follow up. Clin Exp Ophthalmol 35: 649-644.

12. Parodi MB, Spasse S, Iacono P, Di Stefano G, Canziani T, et al. (2008) Subthreshold grid laser treatment of macular edema secondary to branch retinal vein occlusion with micropulse infrared (810 nanomter) diode laser. Ophthalmology 113: 2237-2242.

13. Laursen ML, Moeller F, Sander B, Sjoelie AK (2004) Subthreshold micropulse diode laser treatment in diabetic macular oedema. Br J Ophthalmol 88: 1173-1179.

14. Moorman CM, Hamilton AM (1999) Clinical applications of the MicroPulse diode laser. Eye (Lond) 13: 145-150.

15. Pollack JS, Kim JE, Pulido JS, Burke JM (1998) Tissue effects of subclinical diode laser treatment of the retina. Arch Ophthalmol 116: 1633-1639.

16. Berger JW (1997) Thermal modelling of micropulsed diode laser retinal photocoagulation. Lasers Surg Med 20: 409-415.

17. Li Z, Song Y, Chen X, Chen Z, Ding Q (2015) Biological Modulation of Mouse RPE Cells in Response to Subthreshold Diode Micropulse Laser Treatment. Cell Biochem Biophys 73: 545-552.

18. Tan AM, Chockalingam M, Aquino MC, Lim ZI-L, See JL-S, et al. (2010) Micropulse transscleral diode laser cyclodocoagulation in the treatment of refractory glaucoma. Clin Experiment Ophthalmol 38: 266-272.

19. Chen MF, Kim CH, Coleman AL (2019) Cyclodestructive procedures for refractory glaucoma. Cochrane Database Syst Rev 3: CD012223.

20. Kuchar S, Moster MR, Reamer CB, Waisbourd M (2016) Treatment outcomes of micropulse transscleral cyclodocoagulation in advanced glaucoma. Lasers Med Sci 31: 393-396.

21. Benhatchi N, Bensmail D, Lachkar Y (2019) Benefits of SubCyclo Laser Therapy Guided by High-frequency Ultrasound Biomicroscopy in Patients With Refractory Glaucoma. J Glaucoma 28: 535-539.

22. Schubert HD, Agarwala A, Arbizo V (1990) Changes in aqueous outflow after in vitro neodymium: yttrium aluminum garnet laser cyclodocoagulation. Invest Ophthal Vis Sci 31: 1834-1838.

23. Liu GJ, Mizukawa A, Okisaka S (1994) Mechanism of intraocular pressure decrease after contact transscleral continuous-wave Nd:YAG laser cyclodocoagulation. Ophthalmology 101: 65-79.

24. Sanchez FG, Peirano-Bonomi JC, Grippo TM (2018) Micropulse Transscleral Cyclodocoagulation: A Hypothesis for the Ideal Parameters. Med Hypothesis Discov Innov Ophthalmol 7: 94-100.

25. Lee JH, Shi Y, Amoozgar B, Aderman C, De Alba Campo manes A, et al. (2017) Outcome of Micropulse Laser Transscleral Cyclophotocoagulation on Pediatric Versus Adult Glaucoma Patients. J Glaucoma 26: 936-939.

26. Williams AL, Moster MR, Rahmatnejad K, Resende AF, Horan T, et al. (2018) Clinical Efficacy and Safety Profile of Micropulse Transscleral Cyclophotocoagulation in Refractory Glaucoma. J Glaucoma 27: 445-449.

27. Jammal AA, Costa DC, Vasconcellos JPC, Costa VP (2019) Prospective evaluation of micropulse transscleral diode cyclodocoagulation in refractory glaucoma: 1 year results. Arq Bras Oftalmol 82: 381-388.

28. Bloom PA, Tsai JC, Sharma K, Miller MH, Rice NS, et al. (1997) « Cyclodiode ». Trans-scleral diode laser cyclodocoagulation in the treatment of advanced refractory glaucoma. Ophthalmology 104: 1508-1519; discussion 1519-1520.

29. Cheung JJC, Li KKW, Tang SWK (2019) Retrospective review on the outcome and safety of transscleral diode laser cyclodocoagulation in refractory glaucoma in Chinese patients. Int Ophthalmol 39: 41-46.

30. Keilani C, Benhatchi N, Bensmail D, Abitbol O, Amara A, et al. (2020) Comparative Effectiveness and Tolerance of Subliminal Subthreshold Transscleral Cyclophotocoagulation With a Duty Factor of 25% Versus 31.3% for Advanced Glaucoma. J Glaucoma 29: 97-103.

31. Gavris MM, Olteanu I, Kantor E, Mateescu R, Belicioiu R et al. (2021) Int J Ophthalmol Clin Res 8:126.